logo
Share SHARE
FONT-SIZE Plus   Neg

Myriad Genetics Gets Rights To RAD51C Gene

Myriad Genetics, Inc. (MYGN) said Wednesday it has obtained an exclusive license to intellectual property covering the analysis of the RAD51C gene for risk of hereditary breast and ovarian cancer.

In several studies, mutations in the RAD51C gene have been identified and associated with an increased risk for hereditary breast and ovarian cancer.

RAD51C was identified initially as a susceptibility gene for hereditary breast and ovarian cancer by members of the German Consortium for Hereditary Breast and Ovarian cancers in collaboration with pediatric hematologists and basic scientists predominantly located at the universities of Cologne, Dusseldorf and Munich.

Through this agreement, Myriad has obtained an exclusive, world-wide license, with co-exclusivity in Germany, to provide commercial testing for RAD51C.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Bank of Nova Scotia or otherwise known as Scotiabank, Friday reported lower net profit for the third quarter, in the absence of a year-ago gain. Earnings per share, however, came in line with the Street view. Further, the company said it raised its quarterly dividend by 2 cents. Non-traditional discount and variety stores operator Big Lots Inc. (BIG) Friday reported a decline in net profit for the second quarter, while net sales grew 1.2 percent from the prior year. Comparable sales for the quarter increased 2.8 percent. Google has rejected the European Union's charges that it abused its market power and the demanded that it change the way it ranks online comparison shopping services in its search results, setting up a potentially long legal battle with the EU regulator empowered to levy billions of euros in fines
comments powered by Disqus
RELATED NEWS
Trade MYGN now with 
Follow RTT